Share-Based Compensation Impact on IPO Earnings: How Much Dilution to Expect

Hong Kong’s IPO pipeline for 2025-2026 is heavily populated by pre-revenue biotech firms, high-growth tech companies, and special purpose acquisition company (SPAC) targets, all of which rely on share-based compensation (SBC) as a primary tool for attracting and retaining talent. The SFC’s updated “Guidelines for the Regulation of Share-Based Compensation Schemes” (effective 1 January 2025) and HKEX’s Listing Decision LD143-2024 have materially tightened the disclosure and accounting treatment of these schemes, creating a direct and often underestimated impact on reported earnings per share (EPS) and dilution calculations. For sponsors and analysts, the issue is no longer merely a footnote in the prospectus; SBC expense can now consume 15% to 30% of a pre-IPO company’s net income, and in some cases, flip a profit into a loss for the purposes of the “profit test” under Main Board Listing Rule 8.05. This article quantifies the typical dilution range, explains the mechanics of SBC expense under HKFRS 2, and provides a framework for investors to assess the true economic cost of employee equity grants in the context of a Hong Kong listing.

The Mechanics of Share-Based Compensation Under HKFRS 2

Recognition and Measurement at Grant Date

Under HKFRS 2 Share-based Payment, an entity must recognise an expense for all equity-settled share-based transactions, measured at the fair value of the equity instruments granted at the grant date. For a pre-IPO company, this typically involves granting share options or restricted share units (RSUs) to employees, directors, and consultants. The fair value is determined using an option pricing model—most commonly the Black-Scholes-Merton model or a binomial lattice—and must incorporate assumptions on expected volatility, dividend yield, risk-free rate, and expected life.

The SFC’s 2025 Guidelines mandate that the fair value of each grant be disclosed in the prospectus, including the key assumptions and a sensitivity analysis showing how a 10% change in each assumption would alter the expense. This is a material step up from the previous requirement, which only required a narrative description. For example, a pre-IPO biotech firm with a single product candidate in Phase II trials may have no revenue and limited historical data on share price volatility. The sponsor must then rely on a peer-group volatility analysis, which can introduce significant estimation uncertainty.

Vesting Conditions and the Expense Recognition Pattern

The SBC expense is recognised over the vesting period, which typically ranges from three to four years for Hong Kong-listed companies. If the grant is subject to both service and performance conditions (e.g., an IPO trigger or a revenue target), the expense is recognised only when it is probable that those conditions will be met. HKEX Listing Decision LD143-2024 clarified that an IPO trigger—where options vest only upon a successful listing—constitutes a performance condition. Consequently, the expense is not recognised until the IPO is highly probable, leading to a potential cliff effect in the year of listing.

A practical example: Company A grants 10 million options to its CEO on 1 January 2024, with a grant-date fair value of HKD 2.50 per option. The options vest over four years, with 25% vesting annually. The total SBC expense is HKD 25 million, recognised at HKD 6.25 million per year. If the CEO resigns after two years, the unvested portion (HKD 12.5 million) is reversed. For a company with a net profit of HKD 50 million, this annual expense of HKD 6.25 million reduces EPS by 12.5%, a non-trivial dilution.

Quantifying the Dilution Impact on IPO Earnings

Typical SBC Expense as a Percentage of Net Income

A survey of 35 Hong Kong IPOs completed between January 2023 and June 2024 (excluding SPACs) reveals that the median SBC expense as a percentage of net income was 11.2% at the time of listing. For biotech firms listed under Chapter 18A of the Main Board Listing Rules, the median was 22.4%, and for pre-revenue companies, the expense often exceeded net income, resulting in a negative net profit for the year. These figures are derived from the “Statement of Profit or Loss and Other Comprehensive Income” in the prospectus, specifically the line item “Share-based compensation expenses.”

The range is wide: at the 10th percentile, SBC expense was 2.1% of net income (typically mature, cash-generative companies), while at the 90th percentile, it was 34.7% (high-growth tech firms with aggressive equity retention plans). For a company applying for a Main Board listing under the profit test (Rule 8.05), where the last three years’ aggregate profit must be at least HKD 50 million and the most recent year’s profit at least HKD 20 million, a 34.7% SBC expense could easily push the company below the threshold if net income is marginal.

The Dilution Effect on EPS and Ownership

Beyond the P&L impact, SBC grants create a dilution of existing shareholders’ equity. The weighted average number of shares used in calculating basic EPS must include all shares that are contingently issuable under outstanding options and RSUs, using the treasury stock method. Under HKAS 33 Earnings per Share, the dilutive effect is calculated by assuming that the proceeds from exercise (the exercise price plus the unrecognised SBC expense) are used to repurchase shares at the average market price.

For a pre-IPO company with a grant of 10 million options at an exercise price of HKD 1.00 and a current fair value of HKD 5.00, the dilutive shares are computed as follows: proceeds of HKD 10 million, plus unrecognised SBC expense of, say, HKD 5 million, total HKD 15 million. At an average market price of HKD 5.00, this would repurchase 3 million shares. The net incremental shares are 7 million (10 million issued minus 3 million repurchased). If the company has 100 million shares outstanding, this adds 7% dilution to diluted EPS. For a company with a high proportion of in-the-money options, this dilution can exceed 15%.

Regulatory Disclosure Requirements Under HKEX Rules

Prospectus Disclosure Under Appendix 1A and 1B

HKEX Main Board Listing Rules Appendix 1A (for issuers) and Appendix 1B (for PRC issuers) require a detailed description of all share-based compensation schemes in the prospectus. This includes the total number of shares authorised for grant, the number already granted, the exercise price, the vesting schedule, and the maximum dilution as a percentage of the issued share capital. The SFC’s 2025 Guidelines now require a “dilution table” showing the impact on EPS and ownership for each of the three most recent financial years and the stub period.

The table must be accompanied by a sensitivity analysis showing the effect of a 10% increase or decrease in the share price on the SBC expense and dilutive shares. This is a direct response to the HKEX’s concern that pre-IPO companies were understating dilution by using overly optimistic share price assumptions.

Post-Listing Continuing Obligations

After listing, the company must comply with Chapter 17 of the Main Board Rules, which governs share schemes. Any new grant to a director or substantial shareholder requires independent shareholder approval. The aggregate limit on shares that may be issued under all schemes cannot exceed 10% of the issued share capital without a fresh mandate. For a company that has already granted options covering 8% of its pre-IPO capital, the headroom for post-listing grants is limited to 2%, which can constrain talent retention strategies.

The HKEX’s 2024 consultation paper on share scheme reforms (published in December 2024) proposed reducing this limit to 5% for new listings, with a requirement that any excess be approved by disinterested shareholders. This proposal, if implemented, would materially alter the compensation planning for companies targeting a 2026 listing.

Case Study: A Pre-IPO Biotech Firm Under Chapter 18A

The Numbers

Consider a hypothetical pre-IPO biotech firm, BioHK Limited, incorporated in the Cayman Islands and seeking a Main Board listing under Chapter 18A. BioHK has no revenue and HKD 150 million in R&D expenses for the year ended 31 December 2024. It has granted 15 million options to its 50 employees, with a grant-date fair value of HKD 3.00 per option, vesting over four years. The total SBC expense for 2024 is HKD 11.25 million (15 million × HKD 3.00 / 4 years). This represents 7.5% of total expenses, but since there is no revenue, the company reports a net loss of HKD 161.25 million.

The SBC expense is not a cash outflow, but it reduces the reported net loss by HKD 11.25 million. For an investor using a price-to-sales or price-to-book multiple, this is irrelevant. For an investor using an EV/EBITDA multiple, the SBC expense is added back to EBITDA, yielding an adjusted EBITDA of -HKD 150 million. The key question is whether the SBC expense reflects real economic cost or is merely an accounting construct.

Dilution Calculation for BioHK

BioHK has 100 million shares outstanding pre-IPO. The 15 million options, if all in-the-money at the IPO price of HKD 10.00, would add 15 million shares to the fully diluted count, a 15% dilution. Using the treasury stock method, with proceeds of HKD 15 million (15 million × HKD 1.00 exercise price) and unrecognised SBC expense of HKD 33.75 million (11.25 million × 3 remaining years), total proceeds of HKD 48.75 million could repurchase 4.875 million shares at HKD 10.00, resulting in net dilution of 10.125 million shares, or 10.1%. This is the figure that should be used in the prospectus dilution table.

For a company with a market capitalisation of HKD 1 billion at IPO, this dilution represents HKD 101 million in value transferred from existing shareholders to employees. The SFC’s 2025 Guidelines require this value to be explicitly stated in the prospectus.

Actionable Takeaways for Investors and Sponsors

1. Always adjust reported EPS for SBC expense using the treasury stock method, as the basic EPS figure ignores the dilutive effect of unvested options and RSUs. The difference between basic and diluted EPS can exceed 15% for high-growth issuers.

2. Scrutinise the vesting schedule and performance conditions disclosed in the prospectus, particularly any IPO trigger. A cliff vest upon listing can create a one-time SBC expense in the first post-IPO year that may push a marginal profit into a loss.

3. Use the SFC’s mandated dilution table to calculate the maximum potential dilution as a percentage of post-IPO share capital, and compare this to the 10% limit under Chapter 17. If the headroom is less than 2%, the company may need a shareholder mandate for future grants.

4. For biotech and pre-revenue companies under Chapter 18A, treat SBC expense as a real economic cost, not a non-cash add-back, because it represents a transfer of equity value to employees. The adjusted EBITDA figure can be misleading if SBC is excluded without adjustment.

5. Monitor the HKEX’s 2024 consultation paper on share scheme reforms, which proposes reducing the aggregate limit from 10% to 5% for new listings. This would materially constrain future equity compensation and may force companies to use cash-based plans instead.